Brahmer JR - Search Results

1

Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.

Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, Pitot HC, Hamid O, Bhatia S, Martins R, Eaton K, Chen S, Salay TM, Alaparthy S, Grosso JF, Korman AJ, Parker SM, Agrawal S, Goldberg SM, Pardoll DM, Gupta A, Wigginton JM. Brahmer JR, et al. N Engl J Med. 2012 Jun 28;366(26):2455-65. doi: 10.1056/NEJMoa1200694. Epub 2012 Jun 2. N Engl J Med. 2012. PMID: 22658128 Free PMC article. Clinical Trial.

2

Adjuvant therapy for resected non-small-cell lung cancer: recent advances, emerging agents, and lingering questions.

Lin TL, Brahmer JR. Lin TL, et al. Among authors: brahmer jr. Curr Oncol Rep. 2004 Jul;6(4):251-8. doi: 10.1007/s11912-004-0032-3. Curr Oncol Rep. 2004. PMID: 15161575 Review.

3

Adjuvant treatment in non-small cell lung cancer: Where are we now?

Juergens RA, Brahmer JR. Juergens RA, et al. Among authors: brahmer jr. J Natl Compr Canc Netw. 2006 Jul;4(6):595-600. doi: 10.6004/jnccn.2006.0049. J Natl Compr Canc Netw. 2006. PMID: 16813727 Review.

4

Gemcitabine and vinorelbine in recurrent advanced non-small cell lung cancer: sequence does matter.

Juergens R, Brahmer J, Ettinger D. Juergens R, et al. Cancer Chemother Pharmacol. 2007 Apr;59(5):621-9. doi: 10.1007/s00280-006-0304-8. Epub 2006 Aug 26. Cancer Chemother Pharmacol. 2007. PMID: 16937106 Clinical Trial.

5

Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced cancer.

Carducci MA, Musib L, Kies MS, Pili R, Truong M, Brahmer JR, Cole P, Sullivan R, Riddle J, Schmidt J, Enas N, Sinha V, Thornton DE, Herbst RS. Carducci MA, et al. Among authors: brahmer jr. J Clin Oncol. 2006 Sep 1;24(25):4092-9. doi: 10.1200/JCO.2005.05.3447. J Clin Oncol. 2006. PMID: 16943527 Clinical Trial.

6

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.

Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH. Sandler A, et al. N Engl J Med. 2006 Dec 14;355(24):2542-50. doi: 10.1056/NEJMoa061884. N Engl J Med. 2006. PMID: 17167137 Free article. Clinical Trial.

7

Second-line Therapy for advanced non-small-cell lung cancer.

Hann CL, Brahmer JR. Hann CL, et al. Among authors: brahmer jr. Curr Oncol Rep. 2006 Jul;8(4):243-7. doi: 10.1007/s11912-006-0027-3. Curr Oncol Rep. 2006. PMID: 17254522 Review.

8

"Who should receive epidermal growth factor receptor inhibitors for non-small cell lung cancer and when?".

Hann CL, Brahmer JR. Hann CL, et al. Among authors: brahmer jr. Curr Treat Options Oncol. 2007 Feb;8(1):28-37. doi: 10.1007/s11864-007-0024-2. Curr Treat Options Oncol. 2007. PMID: 17634830 Review.

9

Phase II trial of gemcitabine/carboplatin followed by paclitaxel in patients with performance status=2,3 or other significant co-morbidity (HIV infection or s/p organ transplantation) in advanced non-small cell lung cancer.

Bridges BB, Thomas L, Hausner PF, Doyle LA, Bedor M, Smith R, Brahmer J, Edelman MJ. Bridges BB, et al. Lung Cancer. 2008 Jul;61(1):61-6. doi: 10.1016/j.lungcan.2007.11.009. Epub 2008 Jan 16. Lung Cancer. 2008. PMID: 18201795 Clinical Trial.

10

Chemotherapy for advanced stage non-small cell lung cancer.

Fathi AT, Brahmer JR. Fathi AT, et al. Among authors: brahmer jr. Semin Thorac Cardiovasc Surg. 2008 Fall;20(3):210-6. doi: 10.1053/j.semtcvs.2008.09.002. Semin Thorac Cardiovasc Surg. 2008. PMID: 19038730 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

256 results

Search Page

Filters